SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier’s details
Company name of supplier : MSD
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral) : Category 4
Acute toxicity (Inhalation) : Category 4
Skin irritation : Category 2
Eye irritation : Category 2A
Reproductive toxicity : Category 1B
Specific target organ toxicity - single exposure (Oral) : Category 1 (Central nervous system)
Specific target organ toxicity - single exposure : Category 3
Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

GHS label elements
Hazard pictograms : 

Signal Word : Danger
Hazard Statements : H302 + H332 Harmful if swallowed or if inhaled.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360Df May damage the unborn child. Suspected of damaging
Precautionary Statements:

**Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/ physician if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Storage:**
P405 Store locked up.

**Disposal:**
P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**
None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>:</th>
<th>Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Components</strong></td>
<td>Chemical name</td>
<td>CAS-No.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed or if inhaled.
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
May damage the unborn child. Suspected of damaging fertility.
Causes damage to organs if swallowed.
Causes damage to organs through prolonged or repeated exposure if swallowed.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing: None known.
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version 6.3
Revision Date: 27.08.2021
SDS Number: 1210013-00013
Date of last issue: 26.04.2021
Date of first issue: 10.01.2017

media
Specific hazards during fire fighting
Hazardous combustion products : Exposure to combustion products may be a hazard to health.
Carbon oxides
Nitrogen oxides (NOx)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Keep container tightly closed.
Already sensitized individuals should consult their physician regarding working with respiratory irritants or sensitizers.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin
Wipe limit 0.5 mg/100 cm² Internal

abamectin (combination of avermectin B1a and avermectin B1b) (ISO) 71751-41-2 TWA 15 µg/m³ (OEB 3) Internal

Wipe limit 150 µg/100 cm² Internal

(dl)-a-Tocopheryl acetate 7695-91-2 TWA 5000 ug/m³ (OEB 1) Internal

Biological occupational exposure limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters</th>
<th>Biological specimen</th>
<th>Sampling time</th>
<th>Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone 872-50-4 5-Hydroxy-Urine End of 100 mg/l MX BEI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version: 6.3
Revision Date: 27.08.2021
SDS Number: 1210013-00013
Date of last issue: 26.04.2021
Date of first issue: 10.01.2017

<table>
<thead>
<tr>
<th>N-methyl-2-pyrrolidone</th>
<th>5-Hydroxy-N-methyl-2-pyrrolidone</th>
<th>Urine</th>
<th>End of shift (As soon as possible after exposure ceases)</th>
<th>100 mg/l</th>
<th>ACGIH BEI</th>
</tr>
</thead>
</table>

Engineering measures:
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment
Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Combined particulates and organic vapor type

Hand protection:
Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: liquid
Color: light yellow
Odor: characteristic
Odor Threshold: No data available
pH: Not applicable
SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed or if inhaled.

Product:
Acute oral toxicity: Acute toxicity estimate: 981.33 mg/kg
Method: Calculation method

Acute inhalation toxicity: Acute toxicity estimate: 1.84 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

N-Methyl-2-pyrrolidone:
Acute oral toxicity: LD50 (Rat): 4,150 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Acute dermal toxicity: LD50 (Rat): > 5,000 mg/kg

Ivermectin:
Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version: 6.3  Revision Date: 27.08.2021  SDS Number: 1210013-00013  Date of last issue: 26.04.2021  Date of first issue: 10.01.2017

Test atmosphere: dust/mist

Acute dermal toxicity:
- LD50 (Rabbit): 406 mg/kg
- LD50 (Rat): > 660 mg/kg

Abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
- Acute oral toxicity:
  - LD50 (Rat): 24 mg/kg
  - LD50 (Mouse): 10 mg/kg
  - LD50 (Monkey): 24 mg/kg
  - Symptoms: Dilatation of the pupil

- Acute inhalation toxicity:
  - LC50 (Rat): 0.023 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

Acute dermal toxicity:
- LD50 (Rat): 330 mg/kg
- LD50 (Rabbit): 2,000 mg/kg

(dl)-a-Tocopheryl acetate:
- Acute oral toxicity:
  - LD50 (Rat): > 5,000 mg/kg

- Acute dermal toxicity:
  - LD50 (Rat): > 3,000 mg/kg
  - Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
- Causes skin irritation.

Components:

N-Methyl-2-pyrrolidone:
- Result: Skin irritation

Ivermectin:
- Species: Rabbit
- Result: No skin irritation

Abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
- Species: Rabbit
- Result: No skin irritation

(dl)-a-Tocopheryl acetate:
- Species: Rabbit
- Method: OECD Test Guideline 404
- Result: No skin irritation
**SAFETY DATA SHEET**

**Ivermectin / Abamectin Liquid Formulation**

**Version:** 6.3  
**Revision Date:** 27.08.2021  
**SDS Number:** 1210013-00013  
**Date of last issue:** 26.04.2021  
**Date of first issue:** 10.01.2017

---

**Serious eye damage/eye irritation**
Causes serious eye irritation.

**Components:**

**N-Methyl-2-pyrrolidone:**
- **Species:** Rabbit
- **Result:** Irritation to eyes, reversing within 21 days

**Ivermectin:**
- **Species:** Rabbit
- **Result:** Mild eye irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
- **Species:** Rabbit
- **Result:** Mild eye irritation

**(dl)-a-Tocopheryl acetate:**
- **Species:** Rabbit
- **Result:** No eye irritation
- **Method:** OECD Test Guideline 405

---

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Components:**

**N-Methyl-2-pyrrolidone:**
- **Test Type:** Local lymph node assay (LLNA)
- **Routes of exposure:** Skin contact
- **Species:** Mouse
- **Method:** OECD Test Guideline 429
- **Result:** negative
- **Remarks:** Based on data from similar materials

**Ivermectin:**
- **Routes of exposure:** Dermal
- **Species:** Humans
- **Result:** Does not cause skin sensitization.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
- **Test Type:** Maximization Test
- **Routes of exposure:** Skin contact
- **Result:** Not a skin sensitizer.
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version 6.3  Revision Date: 27.08.2021  SDS Number: 1210013-00013  Date of last issue: 26.04.2021  Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate:
Test Type: Draize Test
Routes of exposure: Skin contact
Species: Humans
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Hamster
Application Route: Ingestion
Method: OECD Test Guideline 475
Result: negative

Ivermectin:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo  
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

(dl)-a-Tocopheryl acetate:  
Genotoxicity in vitro  
Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo  
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

Carcinogenicity  
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:  
Species: Rat  
Application Route: Ingestion  
Exposure time: 2 Years  
Result: negative

Species: Rat  
Application Route: inhalation (vapor)  
Exposure time: 2 Years  
Result: negative

Ivermectin:  
Species: Rat  
Application Route: Oral  
NOAEL: 1.5 mg/kg body weight  
Result: negative  
Remarks: Based on data from similar materials

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

(dl)-a-Tocopheryl acetate:
Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
Result: negative

Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.

Components:
N-Methyl-2-pyrrolidone:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapor)
Result: positive

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Result: positive

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.
<table>
<thead>
<tr>
<th>Substance</th>
<th>Effects on fertility</th>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>NOAEL</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin:</td>
<td>Test Type: Fertility</td>
<td>Species: Rat</td>
<td>Application Route: Oral</td>
<td>Fertility: NOAEL: 0.6 mg/kg body weight</td>
<td>Animal testing did not show any effects on fertility.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Fertility</td>
<td>Species: Mouse</td>
<td>Application Route: Oral</td>
<td>Developmental Toxicity: NOAEL: 0.2 mg/kg body weight</td>
<td>Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Development</td>
<td>Species: Rat</td>
<td>Application Route: Oral</td>
<td>Developmental Toxicity: LOAEL: 0.4 mg/kg body weight</td>
<td>Embryotoxic effects and adverse effects on the offspring were detected. Remarks: The mechanism or mode of action may not be relevant in humans.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Development</td>
<td>Species: Rabbit</td>
<td>Application Route: Oral</td>
<td>Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b) (ISO):</td>
<td>Test Type: Fertility</td>
<td>Species: Rat, male</td>
<td>Application Route: Oral</td>
<td>Effects on fertility.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Two-generation reproduction toxicity study</td>
<td>Species: Rat</td>
<td>Application Route: Oral</td>
<td>Early Embryonic Development: NOAEL: 0.12 mg/kg body weight</td>
<td>Fetotoxicity.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Embryo-fetal development</td>
<td>Species: Mouse</td>
<td>Application Route: Oral</td>
<td>General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight</td>
<td>Developmental Toxicity: NOAEL: 0.2 mg/kg body weight</td>
<td>Cleft palate Remarks: Adverse developmental effects were observed</td>
</tr>
<tr>
<td></td>
<td>Test Type: Embryo-fetal development</td>
<td>Species: Rabbit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects.

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:
Effects on fertility: Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

STOT-single exposure
May cause respiratory irritation.
Causes damage to organs (Central nervous system) if swallowed.

Components:

N-Methyl-2-pyrrolidone:
Assessment: May cause respiratory irritation.

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT-repeated exposure
Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.
abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

<table>
<thead>
<tr>
<th>Routes of exposure</th>
<th>Target Organs</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingestion</td>
<td>Central nervous system</td>
<td>Causes damage to organs through prolonged or repeated exposure.</td>
</tr>
</tbody>
</table>

**Repeated dose toxicity**

**Components:**

**N-Methyl-2-pyrrolidone:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat, male</td>
<td>169 mg/kg</td>
<td>433 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
<td>OECD Test Guideline 408</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>0.5 mg/l</td>
<td>1 mg/l</td>
<td>inhalation (dust/mist/fume)</td>
<td>96 Days</td>
<td>OECD Test Guideline 413</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>826 mg/kg</td>
<td>1,653 mg/kg</td>
<td>Skin contact</td>
<td>20 Days</td>
</tr>
</tbody>
</table>

**Ivermectin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td>0.5 mg/kg</td>
<td>1 mg/kg</td>
<td>Oral</td>
<td>14 Weeks</td>
<td>Central nervous system</td>
<td>Dilatation of the pupil, Tremors, Lack of coordination, anorexia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monkey</td>
<td>1.2 mg/kg</td>
<td>Oral</td>
<td>2 Weeks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>0.4 mg/kg</td>
<td>0.8 mg/kg</td>
<td>Oral</td>
<td>3 Months</td>
<td>spleen, Bone marrow, Kidney</td>
</tr>
</tbody>
</table>
abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Species: Rat
NOAEL: 1.5 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Mouse
NOAEL: 4.0 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Dog
NOAEL: 0.25 mg/kg
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Target Organs: Central nervous system
Symptoms: Tremors, weight loss
Remarks: mortality observed

Species: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

(dl)-a-Tocopheryl acetate:
Species: Rat
NOAEL: 500 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:
Skin contact: Symptoms: Skin irritation

Ivermectin:
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Ingestion:
Symptoms: May cause Tremors, Diarrhea, central nervous system effects, Salivation, tearing

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**N-Methyl-2-pyrrolidone:**
- Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
  Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
  Exposure time: 24 h
  Method: DIN 38412
- Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
  Exposure time: 72 h
  EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
  Exposure time: 72 h
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 12.5 mg/l
  Exposure time: 21 d
  Method: OECD Test Guideline 211
- Toxicity to microorganisms: EC50: > 600 mg/l
  Exposure time: 30 min
  Method: ISO 8192

**Ivermectin:**
- Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
  Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
  Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
  Exposure time: 48 h
- Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
  NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
- Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:

EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants:

EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

Toxicity to fish (Chronic toxicity):

NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

NOEC (Daphnia magna (Water flea)): 0.03 µg/l
Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
Exposure time: 28 d

Toxicity to microorganisms:

EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

(dl)-a-Tocopheryl acetate:

Toxicity to fish:

LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:

EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):
NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
Exposure time: 28 d

Toxicity to microorganisms:
EC50: > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Persistence and degradability

Components:

N-Methyl-2-pyrrolidone:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Stability in water: Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 21.7 - 31%
Exposure time: 28 d
Method: OECD Test Guideline 301C

Bioaccumulative potential

Components:

N-Methyl-2-pyrrolidone:
Partition coefficient: n-octanol/water: log Pow: -0.46
Method: OECD Test Guideline 107

Ivermectin:
Bioaccumulation: Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water: log Pow: 3.22

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Bioaccumulation: Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water: log Pow: 4
Mobility in soil

Components:

Abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environmental compartments: log Koc: > 3.6

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class: 9
Packing group: III
Labels: 9

IATA-DGR

UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes

IMDG-Code

UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class: 9
Packing group: III
Labels: 9
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
MX BEI : Official Mexican Norm NOM-047-SSA1-2011, Environmental Health - Biological exposure indices for workers occupational-ly exposed to chemical agents

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System


Revision Date: 27.08.2021

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8